Bemotrizinol joins the FDA sunscreen monograph — and why the pathway matters more than the molecule

On 9 June 2026, the US Food and Drug Administration issued a Final Administrative Order adding bemotrizinol to the over-the-counter sunscreen monograph. Most of the coverage has framed this as a new ingredient arriving in America. For a regulatory or formulation lead, that is the least interesting part of the story — bemotrizinol has been on shelves in Europe and Asia since around 1999. The part worth your attention is how it got here, because the mechanism is the precedent, and the precedent is what changes your planning.

What the FDA actually did — in precise terms

The distinction between “approved a drug” and “amended a monograph” matters here, and loose wording obscures it. The FDA did not approve a new drug application. It issued a Final Administrative Order adding bemotrizinol to OTC Monograph M020 as a permitted active ingredient at concentrations up to 6%, and determined it generally recognised as safe and effective (GRASE) for adults and children six months and older. The practical effect: once the order takes effect on 9 August 2026, a sunscreen containing bemotrizinol can be marketed without submitting an individual new drug application, provided it complies with the monograph conditions. It is the first new active ingredient added to the US sunscreen monograph since the late 1990s — and, by most counts, brings the number of permitted UV filters in the US to 17. For context, the EU regulates a considerably longer list, because there UV filters are handled as cosmetic ingredients rather than as OTC drugs. That single structural difference explains most of the decades-long gap between US and international sun care.

The real headline: the door is demonstrably open

For twenty years, the practical assumption across the industry was that getting a new UV filter onto the US monograph was effectively impossible. Applications filed in the mid-2000s sat without a workable review mechanism. The 2020 CARES Act rewrote that: buried in its provisions was a new administrative order pathway — the OTC Monograph Order Request (OMOR) — replacing the old rulemaking process with something a sponsor could actually navigate. Bemotrizinol is the first ingredient to travel that pathway end to end. The request was filed in September 2024, the FDA issued a proposed order in December 2025, and the final order followed roughly seven months later. After two decades of stasis, a sub-two-year cycle from request to final order is the signal that matters. The mechanism is no longer theoretical — it has been demonstrated once, from start to finish. That is the strategic takeaway for anyone building a US sun care portfolio: the constraint on new filters has shifted. It is no longer “the FDA has no way to say yes.” It is now a question of data and investment.

The catch formulators need to plan around: exclusivity

Here is the point most consumer coverage omits, and the one that most affects your roadmap. Being on the monograph does not mean bemotrizinol is immediately available for every brand to formulate with. The ingredient’s developer holds a period of marketing exclusivity following the order — reported as eighteen months — which shapes who can bring bemotrizinol products to market first, and when. So “US brands can now use bemotrizinol” is true as a matter of regulatory status but misleading as a matter of timeline. The realistic sequence is a first wave of products tied to the developer and its partners around and after the August 2026 effective date, with broader availability across the wider market expected once exclusivity lapses. If your 2026–2027 formulation plan assumes open access from day one, it needs revisiting.

Why the ingredient is worth the wait technically

Setting the regulatory story aside, the formulation case is genuine. Bemotrizinol is an oil-soluble organic filter that absorbs across both UVA and UVB in a single molecule, and it is notably photostable — it does not degrade under sunlight the way avobenzone, one of the two previously available US UVA filters, is known to. In practice that photostability is the crux: US broad-spectrum products have long leaned on avobenzone, whose UVA protection can fall away during real-world exposure unless carefully stabilised. Bemotrizinol also pairs well with other filters, including mineral actives such as zinc oxide, which can help formulators build higher, more stable broad-spectrum protection with less white cast. For brands whose UVA performance has been constrained by the available US toolkit, it genuinely expands what is possible — which is precisely why the exclusivity timing is worth planning around rather than ignoring.

What this signals for the next filters

The obvious question is whether bemotrizinol opens a wave. The honest answer is: the pathway now works, but it is not a formality. The FDA applies contemporary safety and effectiveness expectations to any new active ingredient, which means a robust data package — absorption, sensitisation, and broader toxicology — is the price of entry. Several other filters common abroad remain off the US monograph, not because they have been rejected on safety, but because the data needed to support a positive GRASE determination has not been assembled. Whether more filters follow therefore depends less on the FDA and more on whether ingredient suppliers judge the US market worth the investment. Bemotrizinol cleared the path largely because one company committed to the multi-year data effort. The precedent lowers the uncertainty for the next sponsor; it does not lower the evidentiary bar.

What US-market brands should do now

• Confirm the effective date in your launch planning: sunscreens with bemotrizinol may be marketed from 9 August 2026, not before.
• Clarify supply access early — factor the developer’s exclusivity period into any roadmap that assumes bemotrizinol availability, and confirm timing with your raw-material supplier.
• Treat compliance as monograph conformity: products must meet all M020 conditions (concentration up to 6%, permitted dosage forms, labelling and effectiveness testing) to rely on GRASE status without a new drug application.
• Revisit UVA claims and testing: if you reformulate to strengthen broad-spectrum performance, ensure your effectiveness testing and label claims are supported.
• Watch the pipeline: the CARES Act pathway is now proven, so track whether suppliers of other international filters move to file, which could reshape the US toolkit over the next few years.

The bottom line

The visible news is a new UV filter in the US after a generation without one. The structural news is that the CARES Act monograph pathway has been shown to work, converting “impossible” into “a matter of data and investment.” For brands, the immediate task is narrow and practical — plan launches around the August 2026 effective date and the developer’s exclusivity — while the longer-term opportunity is to watch a US filter list that has been frozen for decades finally begin to move.

Frequently asked questions

What did the FDA actually do with bemotrizinol?

On 9 June 2026 the FDA issued a Final Administrative Order adding bemotrizinol to the OTC sunscreen monograph (M020) as a permitted active ingredient at concentrations up to 6%, determining it generally recognised as safe and effective (GRASE). The order takes effect on 9 August 2026, after which sunscreens containing it may be marketed without a separate new drug application.

When can brands start selling sunscreens with bemotrizinol in the US?

The order takes effect on 9 August 2026, so compliant products may be marketed from that date. However, the ingredient’s developer holds a period of marketing exclusivity, so broad availability across multiple brands is generally expected to follow later rather than immediately.

Why is bemotrizinol significant if it has been used in Europe for years?

The molecule is not new internationally — it has been used abroad since around 1999. What is new is that it is the first active ingredient added to a US OTC monograph through the streamlined CARES Act administrative order process, which demonstrates that the pathway for new UV filters, long seen as closed, is now workable.

Does this mean other new UV filters will follow quickly?

Not automatically. The pathway is now proven, but the FDA applies contemporary safety and effectiveness data expectations to any new active ingredient. Whether more filters follow depends on whether sponsors are willing to invest in generating the required data package.

How many UV filters are now on the US sunscreen monograph?

The addition of bemotrizinol brings the number of permitted sunscreen active ingredients in the US to 17, compared with a considerably larger list available in the EU, where UV filters are regulated as cosmetic ingredients. CosmeReg helps brands navigate OTC sunscreen monograph compliance, UV filter formulation strategy, and US market entry. Talk to our regulatory team about your sun care portfolio. This article is provided for general information on regulatory developments and does not constitute legal advice. Specific compliance decisions should be confirmed with a qualified regulatory adviser.